FDA Approves World's First Gene Therapy for Genetic Hearing Loss in Record 61 Days
The FDA has approved Regeneron’s Otarmeni, the world’s first dual AAV vector-based gene therapy for severe-to-profound sensorineural hearing loss caused by OTOF gene mutations, with 80% of patients showing hearing improvement in clinical trials.